Extended follow-up beyond 2.5 years demonstrates long-term efficacy in complete responders following epcoritamab monotherapy in relapsed or refractory large b-cell lymphoma (R/R LBCL)
Authors
Karimi, Y. H.Thieblemont, C.
Ghesquieres, H.
Cheah, C. Y.
Clausen, M. R.
Cunningham, D.
Jurczak, W.
Linton, Kim M
Hutchings, M.
Phillips, T.
Farooq, U.
Kim, W. S.
Dinh, M. H.
Ghosh, J.
Pallai, R.
Wielgos-Bonvallet, M.
Eskelund, C.
Lugtenburg, P. J.
Vose, J. M.
Affiliation
The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, United KingdomIssue Date
2024